Methyl 2-(2-{[(Benzyloxy)Carbonyl]Amino}Propan-2-Yl)-5,6-Dihydroxypyrimidine-4-Carb Oxylate

C17H19N3O6

InterMediate E of Raltegravir; 2-(2-(BenzyloxycarbonylaMino)propan-2-yl)-5-hydroxy-6-oxo-1,6-dihydropyriMidine-4-Methyl forMate; Methyl 2-[1-[[(benzyloxy)carbonyl]aMino]-1-Methylethyl]-5,6-dihydroxypyriMidine-4-carboxylate; Methyl2-(1-{[(benzyloxy)carbonyl]aMino}-1-Methylethyl)-5,6-dihydroxypyriMidine-4-carboxyllate; Methyl 2-(2-(benzyloxycarbonyl)propan-2-yl)-5-hydroxy-6-oxo-1,6-dihydropyriMidine-4-carboxylate; Methyl-2-(2-{[(benzyloxy)carbo; Methyl 2-(2-(benzyloxycarbonylamino)propan-2-yl)-5-hydroxy-6-oxo-l,6-dihydropyrimidine-4-carboxylate(Raltegravir); 4-PYRIMIDINECARBOXYLIC ACID, 1,6-DIHYDRO-5-HYDROXY-2-[1-METHYL-1-[[(PHENYLMETHOXY)CARBONYL]AMINO]ETHYL]-6-OXO-, METHYL ESTER;4-PYRIMIDINECARBOXYLIC ACID, 1,6-DIHYDRO-5-HYDROXY-2-[1-METHYL-1-[[(PHENYLMETHOXY)CARBONYL]AMINO]ETHYL]-6-OXO-, METHYL ESTER